Metreleptin Doesn't Improve Glycemic Control in T1DM

Share this content:
Metreleptin Doesn't Improve Glycemic Control in T1DM
Metreleptin Doesn't Improve Glycemic Control in T1DM

MONDAY, March 6, 2017 (HealthDay News) -- For patients with suboptimally controlled type 1 diabetes mellitus (T1DM), metreleptin does not improve glycemic control, but is associated with reductions in body weight and daily insulin dose, according to a study published online Feb. 21 in Diabetes Care.

Chandna Vasandani, Ph.D., from the University of Texas Southwestern Medical Center in Dallas, and colleagues examined the efficacy and safety of metreleptin therapy in five female and three male patients with suboptimally controlled T1DM. Participants received metreleptin subcutaneously twice daily for 20 weeks, followed by four weeks off therapy.

The researchers found that, compared with the baseline value, metreleptin therapy did not lower hemoglobin A1c significantly (mean difference, −0.19 and −0.04 percent, respectively, at 12 and 20 weeks). At weeks 12 and 20 there were significant reductions in mean body weight by 2.6 and 4.7 kg, respectively (P = 0.003), and in daily insulin dose by 12.6 and 15.0 percent, respectively (P = 0.006).

"Metreleptin is safe but may not be efficacious in improving glycemic control in patients with T1DM, although it reduces body weight and daily insulin dose modestly," the authors write.

One author disclosed financial ties to Amylin and Aegerion. Amylin partially funded the study and Aegerion acquired metreleptin after conclusion of the study.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Opioid Rx, Dosing Often Excessive in Dialysis Patients

Opioid Rx, Dosing Often Excessive in Dialysis Patients

High-risk dialysis population also subject to the risks of long-term opioid use

Nonadherence to Statins  ACEIs/ARBs Risky Post MI

Nonadherence to Statins + ACEIs/ARBs Risky Post MI

Adherence to beta-blockers may not be as beneficial to patients after myocardial infarction

Pulse Ox  Auscultation Reliable for Congenital Heart Screening

Pulse Ox + Auscultation Reliable for Congenital Heart ...

The method significantly improves detection rate of major CHD in newborns

is free, fast, and customized just for you!

Already a member?

Sign In Now »